Neoleukin Therapeutics

OverviewSuggest Edit

Neoleukin Therapeutics is a company developing medicines to treat immunological disorders, such as cancer and autoimmunity. It utilizes various computational methods to build therapeutic proteins.
TypePublic
Founded2019
HQSeattle, WA, US
Websiteneoleukin.com

Latest Updates

Employees (est.) (Dec 2019)36
Job Openings12
Revenue (FY, 2018)$25 M
Share Price (Jul 2021)$8.5(-4%)
Cybersecurity ratingBMore

Key People/Management at Neoleukin Therapeutics

Daniel-Adriano Silva

Daniel-Adriano Silva

Vice President Head of Research
Jonathan Drachman

Jonathan Drachman

Chief Executive Officer & President and Director
Cantey Boyd

Cantey Boyd

Board Member
Erin Lavelle

Erin Lavelle

Board Member
Umut Ulge

Umut Ulge

Vice President of clinical development
Sarah Noonberg

Sarah Noonberg

Board Member
Show more

Neoleukin Therapeutics Office Locations

Neoleukin Therapeutics has an office in Seattle
Seattle, WA, US (HQ)
1616 Eastlake Ave E #360
Seattle, WA, US
188 E Blaine St #450
Show all (2)

Neoleukin Therapeutics Financials and Metrics

Neoleukin Therapeutics Revenue

Neoleukin Therapeutics's revenue was reported to be $25 m in FY, 2018
USD

Net income (Q1, 2021)

(14.9m)

Market capitalization (21-Jul-2021)

358.7m

Closing stock price (21-Jul-2021)

8.5

Cash (31-Mar-2021)

178.4m

EV

194.1m
Neoleukin Therapeutics's current market capitalization is $358.7 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

25.0m

General and administrative expense

4.3m5.5m9.3m14.9m15.8m18.8m17.2m

R&D expense

18.1m15.8m28.4m36.3m41.8m24.3m

Operating expense total

22.4m21.3m37.6m51.1m57.6m18.8m41.6m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

25.0m

General and administrative expense

734.8k1.1m986.9k1.5m1.2m1.2m2.0m1.8m2.1m2.7m3.5m3.6m4.3m4.3m4.5m2.6m2.4m10.4m3.6m4.9m5.2m

R&D expense

1.9m4.6m5.3m4.6m3.6m3.7m4.9m9.2m6.1m5.8m10.5m8.5m10.5m18.0m10.7m104.0k9.7m

Operating expense total

2.6m5.8m6.3m6.0m4.8m4.9m6.8m11.1m8.3m8.5m14.0m12.1m14.8m22.3m15.2m2.7m2.4m10.4m3.6m4.9m14.9m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

14.9m39.5m32.3m52.0m76.9m143.1m192.6m

Accounts Receivable

65.4k32.0k

Current Assets

39.3m74.8m103.5m108.8m77.2m143.6m194.5m

PP&E

104.7k89.0k849.0k905.0k400.0k2.1m3.6m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

52.9m17.9m15.9m14.3m14.9m109.4m35.7m22.5m86.2m20.9m27.1m47.1m66.6m99.1m86.7m74.2m72.7m66.3m139.4m129.6m178.4m

Accounts Receivable

66.5k33.4k76.2k57.0k72.0k19.0k

Prepaid Expenses

547.8k424.2k283.9k

Current Assets

56.2m36.3m40.4m35.0m29.8m117.9m69.5m67.6m146.6m122.4m132.2m120.6m94.2m103.2m87.3m74.8m73.2m67.6m139.7m131.0m181.3m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(24.0m)(21.9m)(37.0m)(50.2m)(31.6m)(69.4m)(33.3m)

Depreciation and Amortization

135.9k340.0k785.0k

Accounts Payable

3.6m(450.0k)4.8m1.8m(6.5m)(2.2m)3.0m

Cash From Operating Activities

(17.8m)(20.3m)(30.2m)(44.7m)(31.6m)(15.4m)(24.6m)
USDQ1, 2014

Financial Leverage

1 x
Show all financial metrics

Neoleukin Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Neoleukin Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Neoleukin Therapeutics Online and Social Media Presence

Embed Graph

Neoleukin Therapeutics News and Updates

Neoleukin Therapeutics to Participate in Jefferies Virtual Healthcare Conference

SEATTLE, May 26, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present a…

Neoleukin Therapeutics Announces First Quarter 2021 Financial Results and Corporate Update

- Entered clinical development with first patient dosed in Phase 1 Trial of NL-201 -

Neoleukin Therapeutics to Participate in BofA Securities 2021 Healthcare Conference

SEATTLE, May 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participa…

Neoleukin Therapeutics Announces Clearance to Proceed with NL-201 Phase 1 Clinical Trial in the United States

SEATTLE, April 26, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has removed the cl…

Neoleukin Therapeutics to Host 2020 Financial Results Conference Call and Webcast on March 25, 2021

SEATTLE, March 18, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will report full year 2020 financial results on Thursday, March …

Neoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference

SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present…
Show more

Neoleukin Therapeutics Frequently Asked Questions

  • When was Neoleukin Therapeutics founded?

    Neoleukin Therapeutics was founded in 2019.

  • Who are Neoleukin Therapeutics key executives?

    Neoleukin Therapeutics's key executives are Daniel-Adriano Silva, Jonathan Drachman and Cantey Boyd.

  • How many employees does Neoleukin Therapeutics have?

    Neoleukin Therapeutics has 36 employees.

  • Who are Neoleukin Therapeutics competitors?

    Competitors of Neoleukin Therapeutics include Paige, Jiangsu Hansoh Pharmaceutical Group and 3sbio.

  • Where is Neoleukin Therapeutics headquarters?

    Neoleukin Therapeutics headquarters is located at 1616 Eastlake Ave E #360, Seattle.

  • Where are Neoleukin Therapeutics offices?

    Neoleukin Therapeutics has an office in Seattle.

  • How many offices does Neoleukin Therapeutics have?

    Neoleukin Therapeutics has 2 offices.